Sanger Institute's COSMIC database expands cancer cloud capabilities at the Institute for Systems Biology

The Institute for Systems Biology has embedded the COSMIC data within their Cancer Genomics Cloud (CGC), which is a cloud-based platform that uses Google BigQuery technology to bring unprecedented computing power to researchers around the world

Sanger Institute's COSMIC database expands cancer cloud capabilities at the Institute for Systems Biology

cosmic logo.png

The Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC) team announces a new agreement to provide their data to the U.S.-based Institute for Systems Biology (ISB).

COSMIC is an expert-curated cancer mutation database, and is the world’s largest and most comprehensive resource for exploring the impact of somatic mutations in human cancers.

ISB_Logo.jpg

With this agreement, the ISB have has embedded the COSMIC data within the ISB Cancer Genomics Cloud (CGC), which is a cloud-based platform that uses Google BigQuery technology to bring unprecedented computing power to researchers around the world.

Having COSMIC data within ISB-GCG (isb-cgc.org), which is funded by the National Institutes of Health’s National Cancer Institute, enables new types of cloud-based and cloud-powered analyses across a number of resources, including The Cancer Genome Atlas (TCGA).

COSMIC users can easily sign up via the COSMIC account page and documentation including examples is available to get people up and running quickly.

“It is hugely exciting to be able to embed our carefully and manually curated COSMIC data within ISB-CGC. This enables scientists to study mutation trends at high resolution and perform integrative analyses of COSMIC and TCGA [The Cancer Genome Atlas] data using unparalleled computed power.”

Dr. Simon Forbes, Head of COSMIC (Catalogue of Somatic Mutations)

“ISB [Institute for Systems Biology] has always valued open access to data. This agreement with COSMIC augments the ISB-CGC [ISB-Cancer Genomics Cloud] platform and makes it an even more useful resource for the cancer research community.”

Dr. Ilya Shmulevich, whose lab developed the ISB-CGC platform

Notes to Editors
Selected Websites
Is cancer a genetic disease?FactsIs cancer a genetic disease?
Cancer is the most common human genetic disease. The transition from a normal cell to a malignant cancer is driven by changes to a cell’s DNA, also known as mutations.

Cancer: Rogue CellsVideoCancer: Rogue Cells
This animation describes how cancer grows within the body and how different factors can lead to cancer development.

What is a mutation?FactsWhat is a mutation?
A mutation is a change that occurs in our DNA sequence, either due to mistakes when the DNA is copied or as the result of environmental factors such as UV light and cigarette smoke. 

Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Wellcome Sanger Institute calls for the free movement of scientists across European borders following Brexit

The Institute has provided evidence for the UK Government Science and Technology Committee’s inquiry into an immigration system that works for science and innovation

Genomics offers new treatment options for infants with range of soft tissue tumours

Scientists uncover the genetic changes causing a group of related infant cancers

Genetic discovery will help clinicians identify aggressive versus benign bone tumours

A genetic change affecting the transcription factor, FOS is specific to osteoblastoma, distinguishing it from osteosarcoma